Genentech’s gantenerumab granted FDA breakthrough designation in AD
Gantenerumab is an investigational IgG1 antibody designed to block certain forms of amyloid beta and eliminate brain amyloid…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
12 Oct 21
Gantenerumab is an investigational IgG1 antibody designed to block certain forms of amyloid beta and eliminate brain amyloid…
11 Oct 21
The company claims that Tavneos is the first orally-administered inhibitor of the complement 5a receptor to receive the…
11 Oct 21
Sandoz obtains rights to three established brands, including Zinnat, Zinacef and Fortum, which had combined sales of around…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Oct 21
The new facility includes drug substance manufacturing along with fill/finish and packaging
07 Oct 21
Voyager will receive an upfront payment of $30m, potential option exercise fees and milestone payments of up to…
06 Oct 21
The company’s submission of antibody cocktail is based on safety and efficacy data from the Phase 3 PROVENT…
05 Oct 21
The US FDA has granted BTD for Enhertu based on results from the DESTINY-Breast03 trial, in which Enhertu…
05 Oct 21
Cipla will expand access to Lilly’s diabetes drugs by leveraging its distribution capabilities and engaging its professionals
04 Oct 21
Tecartus has received breakthrough therapy designation and a priority review from the FDA and is also being evaluated…
04 Oct 21
Merck intends to pursue the US FDA emergency use authorisation for the drug, and file regulatory applications with…